Media coverage about Amyris (NASDAQ:AMRS) has been trending somewhat negative this week, according to Alpha One Sentiment Analysis. The research group, a subsidiary of Accern, rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amyris earned a coverage optimism score of -0.01 on Alpha One’s scale. Alpha One also assigned media coverage about the biotechnology company an impact score of 71 out of 100, meaning that recent media coverage is likely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Alpha One Sentiment’s analysis:
Shares of Amyris (NASDAQ AMRS) opened at 0.22 on Tuesday. Amyris has a 12 month low of $0.21 and a 12 month high of $1.21. The stock’s 50 day moving average is $0.40 and its 200 day moving average is $0.57. The firm’s market capitalization is $65.36 million. Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The company had revenue of $13 million for the quarter, compared to analyst estimates of $32.30 million. During the same period in the prior year, the firm posted ($0.17) earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Equities research analysts forecast that Amyris will post ($0.26) earnings per share for the current fiscal year.
In other news, Director Patrick Y. Yang acquired 300,000 shares of the business’s stock in a transaction on Friday, May 19th. The shares were purchased at an average cost of $0.29 per share, with a total value of $87,000.00. Following the acquisition, the director now directly owns 153,000 shares of the company’s stock, valued at $44,370. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder (Mauritius) Pte Ltd Maxwell sold 346,429 shares of Amyris stock in a transaction on Monday, March 13th. The stock was sold at an average price of $0.50, for a total transaction of $173,214.50. The disclosure for this sale can be found here. Insiders have sold a total of 4,975,546 shares of company stock worth $2,725,677 over the last ninety days. Insiders own 48.70% of the company’s stock. Amyris Company Profile